Antibody drug conjugates (ADCs) combine a cancer-killing drug with an antibody targeted to deliver the therapy directly to a tumor. Tubulis, a startup company, is working to improve on current ADC designs by developing technologies that enhance stability and target specificity. Tubulis has secured €128 million in funding to support its research and is moving closer to clinical trials. The company’s lead programs, targeting proteins expressed by solid tumors, are optimized for long-lasting effectiveness with minimal off-target toxicity. Tubulis’ technology has attracted the interest of Bristol Myers Squibb, which paid to access the company’s ADC payloads. Additional partnerships are possible, but Tubulis remains focused on developing its internal drug pipeline.
Source link
A Startup’s Flexibility With ADC Cancer Drugs Attracts €128M for Clinical Trials
